查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829123

1 型糖尿病治疗市场（按胰岛素类型、给药方式、患者年龄层、分销管道和最终用户划分）—2025-2032 年全球预测

Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Patient Age Group, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，1 型糖尿病药物市场将成长至 390.7 亿美元，复合年增长率为 9.32%。

主要市场统计数据
基准年2024年 191.4亿美元
预计2025年 209.3亿美元
预测年份：2032年 390.7亿美元
复合年增长率（%） 9.32%

策略介绍框架，阐述临床创新、政策转变和商业动态之间的相互作用，重新定义 1 型糖尿病照护和相关人员的优先事项

1型糖尿病仍然是一种复杂的慢性疾病，需要精准的临床管理、持续的技术创新以及支付者和医疗机构的协调参与。过去十年，胰岛素製剂和给药技术的临床进展与监管部门对数位医疗解决方案和可负担性的关注相辅相成。因此，产业、临床和政策相关人员正在重新评估各自的优先事项，以更好地将治疗价值与以病人为中心的医疗服务结合。

本执行摘要概述了推动第1型糖尿病治疗的关键力量，并强调了临床创新如何与供应链动态和商业策略交织在一起。此外，它还强调了当代政策辩论和拟议关税调整的影响，这些因素可能对产品流动和成本结构产生重大影响。本摘要旨在透过阐明临床需求、技术能力和经济约束之间的交汇点，为策略规划提供综合基础。

读者将找到一个简洁的当前环境框架，一个清晰且基于证据的变革动态解释，以及一条协调专案和商业性应对措施的实用路径。本书的引言也为后续更深入的讨论奠定了基础，涵盖细分市场、区域模式、公司定位以及可操作的建议，旨在帮助领导者将洞察转化为优先行动。

临床进展、医疗服务创新和政策压力如何重塑 1 型糖尿病治疗的商业策略和患者期望

1型糖尿病治疗领域正在经历变革性变革，这得益于製剂科学、给药系统、数位整合以及强调可及性和可负担性的政策的同步进步。临床上，胰岛素类似物製剂和辅助性治疗的逐步改进，加上闭合迴路胰岛素给药和感测器技术的创新，正在提升血糖稳定性和生活品质的前景。这些技术变革正在改变临床医生的处方方式、患者的日常用药管理方式以及支付方评估价值提案的方式。

同时，商业模式也在不断演变。製造商正在透过胰岛素类型和给药方式来丰富产品系列，同时投资于患者支援服务和数位化依从性工具，以使其产品更具差异化。从注射笔和帮浦到贴片装置和预填充註射器，给药方式的创新正在将医疗服务中心转向更自主的家庭管理，并为竞争差异化创造新的管道。监管机构和报销机构越来越关注现实世界的疗效和成本效益，推动更严格的证据要求，并更加重视卫生经济学和疗效研究。

此外，生物相似药、策略伙伴关係以及加速互补技术取得的定向收购正在重塑竞争格局。这些因素，加上公众对定价和分销实践的审查力度不断加大，正在建立一个更加整合的生态系统，在这个生态系统中，临床疗效、患者体验和可负担性必须相互协调。能够协调产品开发、服务模式和政策参与的相关人员将更有能力获取价值并改善病患治疗效果。

评估 2025 年美国关税变化对第 1 型糖尿病药物供应链、定价动态和上市策略的累积影响

2025年美国新关税的实施，将引发整个1型糖尿病价值链的供应链设计、筹资策略和成本管理的重要考量。进口零件、成品和包装材料的关税调整可能会增加胰岛素製剂和给药系统的到岸成本，迫使製造商和经销商重新考虑其采购布局和库存策略。为此，许多公司将评估近岸外包、双重采购或增加本地生产，以缓解进口关税和相关的物流波动。

这些政策转变也将影响定价动态以及与付款人和综合交付网路的合约关係。日益增长的成本压力可能会加速有关製造商返利、处方药目录配置以及将医疗设备报销与已证实的临床结果挂钩的捆绑式医疗安排的谈判。同时，单位成本的上升（尤其是在共同支付持续的情况下）可能会对患者的负担能力造成压力，从而加剧患者援助计划和替代资金筹措模式的紧迫性。

从营运角度来看，关税可能会增加与库存积压和通路库存相关的财务风险，从而扰乱既定的新产品发布和生命週期管理时间表。因此，产品团队需要整合产品发布计划和采购合同，并将关税的影响纳入考虑。重要的是，关税环境将提升面向製造设计决策的策略价值，从而减少对关税投入的依赖，并提升数位化工具的策略价值，从而优化分销效率。总而言之，2025年的关税环境将成为整个1型糖尿病生态系统中更具弹性、更具成本意识和更具地域导向的供应链策略的催化剂。

关键细分洞察揭示了胰岛素类型、给药方式、患者人口统计、分销选择和最终用户偏好如何独特地塑造临床和商业策略

細項分析揭示了差异化的临床和商业性途径，值得我们给予单独的策略关注。根据胰岛素类型，中效製剂、长效类似物、速效製剂和短效胰岛素製剂的产品开发和临床定位有所不同，每类製剂针对不同的治疗适应症和依从性。胰岛素类型的选择也会与给药偏好和临床方案相互影响，进而影响处方协商和处方模式。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 每週一次的 GLP-1 受体促效剂的出现改善了第 1 型糖尿病患者的血糖控制
  • 数位健康整合推动封闭回路型胰岛素输送系统的快速应用
  • 以合併使用升糖素减少低血糖发作为目标的双激素帮浦治疗进展
  • 开发口服胰岛素类似物产品线，以提高患者依从性并减少注射负担
  • 免疫调节疗法在第一型糖尿病早期诊断中维持β细胞功能的作用
  • 扩展连续酮监测技术以预防门诊糖尿病酮酸症

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 1 型糖尿病治疗市场（按胰岛素类型）

  • 中效型
  • 长效
  • 快速起效
  • 短效

9. 1 型糖尿病药物市场（依给药方式）

  • 笔
    • 免洗笔
    • 可重复使用的笔
  • 泵浦
    • 胰岛素帮浦
    • 贴片帮浦
  • 注射器
    • 预填充式注射器
    • 管瓶和注射器

第 10 章：1 型糖尿病治疗市场（依患者年龄层）

  • 成人
  • 老年人
  • 孩子们

第 11 章 1 型糖尿病药物市场（依分销管道）

  • 离线
  • 在线的

第 12 章：1 型糖尿病药物市场（按最终用户划分）

  • 诊所
    • 基层医疗诊所
    • 专科诊所
  • 居家护理
    • 看护者管理
    • 自我管理
  • 医院
    • 私立医院
    • 公立医院

第 13 章 1 型糖尿病药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章 1 型糖尿病药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章 1 型糖尿病药物市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Novo Nordisk A/S
    • Sanofi SA
    • Eli Lilly and Company
    • Biocon Limited
    • Viatris Inc.
    • Wockhardt Limited
    • MannKind Corporation
    • Dr. Reddy's Laboratories Limited
    • Glenmark Pharmaceuticals Limited
    • Lupin Limited
Product Code: MRR-43676CF429EB

The Type 1 Diabetes Drug Market is projected to grow by USD 39.07 billion at a CAGR of 9.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 19.14 billion
Estimated Year [2025] USD 20.93 billion
Forecast Year [2032] USD 39.07 billion
CAGR (%) 9.32%

A strategic introduction framing the interplay of clinical innovation, policy shifts, and commercial dynamics that are redefining Type 1 diabetes care and stakeholder priorities

Type 1 diabetes remains a complex chronic condition that requires precise clinical management, continuous technological innovation, and coordinated payer and provider engagement. Over the past decade, clinical advances in insulin formulation and delivery technologies have been complemented by digital health solutions and regulatory attention on affordability, which together have redefined expectations for patient outcomes and system-level efficiency. As a result, stakeholders across industry, clinical practice, and policy are reassessing priorities to better align therapeutic value with patient-centered care.

This executive summary synthesizes the dominant forces driving the Type 1 therapeutic landscape, highlighting how clinical innovations intersect with supply chain dynamics and commercial strategies. It also surfaces the implications of contemporary policy debates and proposed tariff shifts that may materially affect product flows and cost structures. The aim is to provide an integrated foundation for strategic planning by clarifying where clinical need, technological capability, and economic constraints converge.

Readers will find a concise framing of the current environment, an evidence-based articulation of transformative dynamics, and pragmatic pathways for aligning programmatic and commercial responses. In doing so, this introduction sets the stage for deeper examination of segmentation, regional patterns, company positioning, and actionable recommendations that follow, ensuring that leaders can translate insight into prioritized action.

How converging clinical advances, delivery innovation, and policy pressure are reshaping commercial strategies and patient expectations across Type 1 diabetes care

The therapeutic landscape for Type 1 diabetes is experiencing transformative shifts driven by simultaneous advances in formulation science, delivery systems, digital integration, and policy focus on access and affordability. On the clinical front, incremental improvements in insulin analogs and adjunctive therapies are being matched by innovations in closed-loop insulin delivery and sensor technologies, which together are raising expectations for glycemic stability and quality-of-life improvements. These technological inflections are changing how clinicians prescribe, how patients manage daily regimens, and how payers evaluate value propositions.

Concurrently, commercial models are evolving: manufacturers are diversifying product portfolios across insulin types and delivery formats while investing in patient support services and digital adherence tools to differentiate offerings. Delivery mode innovation - from pens and pumps to patch devices and prefilled injectables - is shifting the locus of care toward more autonomous, home-based management and creating new channels for competitive differentiation. Regulatory and reimbursement agencies are increasingly focused on real-world outcomes and cost-effectiveness, prompting tighter evidence requirements and greater emphasis on health economics and outcomes research.

Moreover, the competitive field is being reshaped by biosimilars, strategic partnerships, and targeted acquisitions that accelerate access to complementary technologies. These factors, in combination with heightened public scrutiny of pricing and distribution practices, are producing a more integrated ecosystem in which clinical efficacy, patient experience, and affordability must be addressed in concert. Stakeholders that align product development, service models, and policy engagement will be better positioned to capture value and deliver improved patient outcomes.

Assessing the cumulative effects of the United States tariff changes in 2025 on supply chains, pricing dynamics, and commercial launch strategies within Type 1 diabetes therapeutics

The introduction of new tariff measures in the United States in 2025 creates material considerations for supply chain design, procurement strategies, and cost management across the Type 1 diabetes value chain. Tariff adjustments on imported components, finished devices, or packaging materials can increase landed costs for insulin products and delivery systems, prompting manufacturers and distributors to reconsider sourcing footprints and inventory strategies. In response, many organizations will evaluate nearshoring, dual-sourcing, or increased local manufacturing to mitigate exposure to import duties and related logistical volatility.

These policy shifts also influence pricing dynamics and contracting relationships with payers and integrated delivery networks. Heightened cost pressure can accelerate negotiation around manufacturer rebates, formulary placement, and bundled care arrangements that link device reimbursement to demonstrated clinical outcomes. At the same time, higher unit costs may strain affordability for patients, especially where out-of-pocket exposure persists, thereby intensifying the urgency for patient-assistance programs and alternative financing models.

Operationally, tariffs can disrupt established timelines for new product launches and lifecycle management by increasing the financial risk associated with inventory accumulation and channel stocking. Consequently, product teams will need to integrate tariff sensitivity into commercial launch plans and procurement contracts. Importantly, the tariff environment amplifies the strategic value of design-for-manufacture decisions that reduce dependence on tariffed inputs and of digital tools that optimize distribution efficiency. Taken together, the 2025 tariff landscape is a catalyst for more resilient, cost-aware, and locally orientated supply chain strategies across the Type 1 diabetes ecosystem.

Key segmentation insights revealing how insulin types, delivery modalities, patient age cohorts, distribution choices, and end-user settings uniquely shape clinical and commercial strategies

Segmentation analysis reveals differentiated clinical and commercial pathways that merit discrete strategic attention. Based on insulin type, product development and clinical positioning diverge across intermediate-acting formulations, long-acting analogs, rapid-acting preparations, and short-acting insulins, with each class serving distinct therapeutic indications and adherence profiles. The selection of insulin type also interacts with delivery preferences and clinical protocols, influencing formulary negotiations and prescribing patterns.

Based on delivery mode, the ecosystem spans pens, pumps, and syringes, with significant nuance embedded in device subtypes. Pen options include disposable and reusable pens that offer different trade-offs in cost, convenience, and environmental profile. Pump technologies bifurcate into traditional insulin pumps and emerging patch pump designs, each creating distinct opportunities for integration with continuous glucose monitoring and algorithmic dosing. Syringe-based delivery remains relevant through both prefilled syringes and vial-and-syringe offerings, serving specific patient segments and clinical situations where simplicity or cost-containment is prioritized.

Based on patient age group, therapeutic needs and service delivery models differ across adult, geriatric, and pediatric populations, with pediatric care emphasizing caregiver education and tailored dosing, geriatric care prioritizing comorbidity management and simplified regimens, and adult care spanning a broad spectrum of lifestyle and occupational considerations. Based on distribution channel, offline and online pathways are both influential; brick-and-mortar pharmacies and clinics maintain importance for immediacy and clinical oversight, while digital pharmacies and telehealth platforms are expanding access and facilitating home delivery and remote monitoring. Based on end user, clinics, home care, and hospitals represent distinct demand centers. Clinics are further segmented into primary care and specialty clinics, each with their own prescribing behavior and procurement models. Home care differentiates between caregiver administration and self administration, which shapes education and support needs. Hospitals divide into private and public institutions with divergent procurement cycles, reimbursement pressures, and acute care priorities. Integrating these segmentation dimensions enables targeted product design, differentiated service offerings, and finely tuned commercialization strategies.

Regional dynamics and differentiated entry strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access, adoption, and commercialization

Regional dynamics create differentiated opportunity windows and operational challenges for product developers and suppliers. In the Americas, commercial dynamics are characterized by a mix of advanced delivery adoption, intense payer negotiation, and ongoing public policy attention to affordability and patient assistance, which together influence pricing strategies, reimbursement pathways, and patient access programs. The Americas also show concentrated pockets of digital health adoption that accelerate the uptake of integrated insulin delivery and monitoring systems.

In Europe, Middle East & Africa, heterogeneous regulatory environments and variable healthcare financing structures create a mosaic of entry requirements and reimbursement timelines. This region often requires tailored market access strategies that account for national formulary processes, tendering behaviors, and local manufacturing incentives. Emerging markets within the region present growth potential but demand flexible pricing and distribution approaches that match local healthcare capacities and procurement norms.

In Asia-Pacific, demand is driven by a combination of rapid technology adoption in some high-income markets and broad population-level needs in larger middle-income countries. Local manufacturing capabilities, strategic partnerships, and policy initiatives to improve chronic disease management shape product design and commercialization. Across all regions, differences in insulin type preference, device adoption rates, distribution channel maturity, and payer architecture necessitate region-specific pathways to market entry, clinical evidence generation, and patient support programming.

How integrated product, device, and service strategies are reshaping competitive positioning and driving new partnerships and differentiators across the Type 1 diabetes field

The competitive landscape in Type 1 diabetes therapeutics is increasingly defined by integrated offers that combine pharmacology, delivery technology, and digital services. Leading pharmaceutical innovators continue to invest in next-generation insulin analogs and device platforms while emerging players and device specialists introduce disruptive form factors such as patch pumps and algorithm-enabled closed-loop systems. Strategic collaborations between drug developers, medtech firms, and digital health vendors are accelerating time-to-market for integrated solutions and creating bundled offerings that are attractive to health systems seeking measurable improvements in outcomes.

Concurrently, competition is intensifying around service ecosystems: patient support programs, remote monitoring, and adherence-enhancing solutions have become standard differentiators. Companies that can demonstrate improvements in real-world glycemic control, reductions in acute event utilization, and clear pathways to lowering total cost of care are securing more favorable payer engagements and formulary access. Supply chain agility and manufacturing footprint also matter more as tariff and trade considerations prompt buyers to prioritize suppliers with resilient, localized capabilities.

New entrants and specialized device makers exert pressure on incumbents by focusing on niche patient needs, simplified user experiences, and lower-cost manufacturing models. In response, established firms are leveraging scale, regulatory experience, and broad clinical datasets to defend positions while selectively partnering to fill capability gaps. The net effect is a landscape in which clinical differentiation, product-service integration, and operational resilience determine competitive advantage.

Actionable strategic priorities for industry leaders to align clinical innovation, supply resilience, and patient access while maximizing commercial and therapeutic impact

Industry leaders should prioritize a coordinated set of actions to navigate clinical innovation, policy dynamics, and supply chain shifts. First, integrate device and digital service development with core pharmaceutical programs to deliver bundled value propositions that address adherence, monitoring, and outcomes measurement. This alignment should include clear evidence generation plans that emphasize real-world outcomes and health economic benefit, enabling stronger payer conversations and differentiated contracting.

Second, reassess sourcing and manufacturing strategies to reduce exposure to tariff volatility and logistical disruption. Where feasible, pursue localized manufacturing or strategic partnerships that shorten supply chains and improve responsiveness. Concurrently, embed tariff sensitivity into commercial forecasting and launch planning so procurement and pricing decisions reflect potential cost pressures.

Third, tailor commercialization pathways by leveraging segmentation insights: align product variants and service offers to the clinical needs of adult, geriatric, and pediatric populations; optimize delivery-mode portfolios across pens, pumps, and syringe formats; and adapt distribution strategies to regional channel maturity. Fourth, enhance patient affordability and access through creative contracting, patient-assistance programs, and digital-enabled adherence initiatives that reduce total cost of care and improve uptake.

Finally, invest in collaborative ecosystems that bridge pharmaceutics, medtech, and digital health expertise. Form strategic alliances with device innovators and data analytics firms to accelerate integrated solutions and scale evidence capture. By combining these strategic moves, organizations can strengthen market positioning while advancing patient-centered outcomes.

Transparent multi-method research methodology combining primary interviews, scenario analysis, and cross-regional comparison to ensure robust and reproducible insights

This research synthesizes primary and secondary sources using a multi-method approach designed to ensure thematic depth and methodological transparency. Primary inputs include structured interviews with clinical specialists, procurement leaders, and industry executives, supplemented by subject-matter workshops that validated emergent hypotheses and triangulated qualitative insights. Secondary inputs encompass peer-reviewed clinical literature, regulatory guidance documents, and public policy statements that inform analysis of clinical practice trends and reimbursement dynamics.

Analytical methods combined thematic coding of qualitative interviews with comparative evaluation of device and therapy feature sets. Scenario analysis was employed to assess the operational implications of tariff changes and supply chain disruptions, while value-mapping exercises linked clinical endpoints to potential payer considerations. Cross-regional comparison used consistent frameworks to surface differences in regulatory, reimbursement, and distribution environments.

Quality assurance involved iterative review cycles with external clinical advisors and industry experts to test assumptions and refine conclusions. Wherever possible, claims are anchored to verifiable sources and subject-matter validation. Limitations and assumptions are documented in the full report, along with appendices that detail interview methodologies, sampling frames, and analytical templates to support reproducibility and client scrutiny.

Concluding synthesis that integrates clinical, commercial, and policy imperatives to guide strategic choices and catalyze targeted action in Type 1 diabetes care

In conclusion, the Type 1 diabetes landscape is undergoing a sustained reorientation driven by advances in insulin formulations, delivery innovation, digital integration, and heightened policy scrutiny around affordability and access. These forces are compelling stakeholders to design solutions that combine pharmacologic efficacy with user-friendly delivery mechanisms and supportive services that demonstrate measurable real-world outcomes. The increasing complexity of payer expectations and the potential implications of trade policy changes necessitate more integrated planning across R&D, supply chain, and commercial functions.

To succeed in this environment, organizations must adopt holistic strategies that align product differentiation, evidence generation, and channel execution. This includes segment-specific product and service design, resilient sourcing strategies, and partnerships that close capability gaps quickly. By doing so, manufacturers and providers can better meet clinician and patient needs while navigating economic and regulatory uncertainty.

Ultimately, the organizations that most effectively blend clinical innovation with operational resilience and patient-centric commercial models will be best positioned to deliver improved outcomes and sustainable value for people living with Type 1 diabetes. The insights in this executive summary are intended to inform those strategic choices and to catalyze targeted action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of once-weekly GLP-1 receptor agonists showing improved glycemic control in type 1 patients
  • 5.2. Rapid adoption of hybrid closed-loop insulin delivery systems driven by digital health integration
  • 5.3. Advances in dual-hormone pump therapy targeting glucagon co-administration to reduce hypoglycemic events
  • 5.4. Pipeline development of oral insulin analogs aiming to improve patient adherence and reduce injection burden
  • 5.5. Role of immunomodulatory therapies in preserving beta cell function during early type 1 diabetes diagnosis
  • 5.6. Expansion of continuous ketone monitoring technologies to prevent diabetic ketoacidosis in outpatient settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 1 Diabetes Drug Market, by Insulin Type

  • 8.1. Intermediate-Acting
  • 8.2. Long-Acting
  • 8.3. Rapid-Acting
  • 8.4. Short-Acting

9. Type 1 Diabetes Drug Market, by Delivery Mode

  • 9.1. Pen
    • 9.1.1. Disposable Pen
    • 9.1.2. Reusable Pen
  • 9.2. Pump
    • 9.2.1. Insulin Pump
    • 9.2.2. Patch Pump
  • 9.3. Syringe
    • 9.3.1. Prefilled Syringe
    • 9.3.2. Vial And Syringe

10. Type 1 Diabetes Drug Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Type 1 Diabetes Drug Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Type 1 Diabetes Drug Market, by End User

  • 12.1. Clinics
    • 12.1.1. Primary Care Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Home Care
    • 12.2.1. Caregiver Administration
    • 12.2.2. Self Administration
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Type 1 Diabetes Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Type 1 Diabetes Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Type 1 Diabetes Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novo Nordisk A/S
    • 16.3.2. Sanofi S.A.
    • 16.3.3. Eli Lilly and Company
    • 16.3.4. Biocon Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Wockhardt Limited
    • 16.3.7. MannKind Corporation
    • 16.3.8. Dr. Reddy's Laboratories Limited
    • 16.3.9. Glenmark Pharmaceuticals Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE